Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
REGULATORY
Qalsody, Zepbound, Zeposia Up for Advisory Panel Review on Dec. 2
Biogen’s amyotrophic lateral sclerosis (ALS) treatment tofersen and Eli Lilly’s obesity drug tirzepatide are entering the final stretch of regulatory reviews in Japan, with a key health ministry advisory panel now scheduled to discuss their approval on December 2. The…
To read the full story
Related Article
- Qalsody, Zepbound, Zeposia Inch Closer to Japan Approval with Panel OK
December 3, 2024
- Biogen Files Tofersen as Japan’s 1st Genetic ALS Drug
May 22, 2024
- Lilly Files Tirzepatide for Obesity in Japan, Ties Up with Mitsubishi
May 9, 2024
- Argenx Seeks Label Expansion for Vyvdura in Japan
April 26, 2024
- Santen Seeks Japan Nod for Eye Drop Targeting Myopia
February 29, 2024
- BMS Files Ulcerative Colitis Med Ozanimod in Japan
February 27, 2024
- PeptiDream to Codevelop Lilly's Alzheimer’s Diagnostic Tauvid in Japan
November 25, 2022
REGULATORY
- Trump Signs Off on Up to 100% Tariffs on Drugs; Japan Rate Set at 15%
April 3, 2026
- Japan Launches Task Force to Secure Critical Supplies amid Middle East Crisis
April 3, 2026
- MHLW Streamlines Lot Release Procedures for Vaccines, Blood Products
April 3, 2026
- MHLW Allows Outer Packaging Labeling for Regenerative Medicine Products
April 3, 2026
- MHLW’s Drug Supply Monitoring System Now Up and Running
April 3, 2026
Japan will overhaul its R&D tax credit regime in its FY2026 reform, introducing a new strategic category alongside existing frameworks.…
Strategic Talent Acquisition in the Japanese Life Sciences Sector: Your Market Intelligence Briefing
Focus: How to Get the Talent You Need in a Tough MarketThe Japanese life sciences sector presents a challenging landscape for global companies. To succeed, you must move beyond reactive hiring and adopt a truly strategic talent acquisition model. Our…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…